title: Mitigation of radiation injuries via suppression of the renin-angiotensin system: emphasis on radiation nephropathy.
abstract: Radiation nephropathy and other normal tissue radiation injuries can be successfully mitigated, and also treated, by antagonists of the renin-angiotensin system (RAS). This implies a mechanistic role for that system in radiation nephropathy, yet no evidence exists to date of activation of the RAS by irradiation. RAS antagonists, including angiotensin converting enzyme inhibitors and angiotensin receptor blockers, are the standard of care in the treatment of subjects with other chronic progressive kidney diseases, in which they exert benefit by reducing both glomerular and tubulo-interstitial injury. These drugs are likely to act in a similar way to mitigate radiation nephropathy.
authors.affiliation: Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. Eric.Cohen2@va.gov
authors.forename: E P
authors.initials: EP
authors.lastname: Cohen
authors.forename: B L
authors.initials: BL
authors.lastname: Fish
authors.forename: J E
authors.initials: JE
authors.lastname: Moulder
mesh_terms: D057911:Angiotensin Receptor Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000528:radiation effects; D007674:Kidney Diseases / Q000188:drug therapy* / Q000209:etiology* / Q000517:prevention & control; D011832:Radiation Injuries / Q000188:drug therapy* / Q000517:prevention & control; D012084:Renin-Angiotensin System / Q000187:drug effects*
chemical_list: D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors